|
|
|
Insider
Information: |
Lampert Mark N |
Relationship: |
10% Owner |
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
44 |
|
Direct
Shares |
110,838,010 |
|
Indirect Shares
|
88,557,834 |
|
|
Direct
Value |
$1,508,826,551 |
|
|
Indirect Value
|
$1,659,242,856 |
|
|
Total
Shares |
199,395,844 |
|
|
Total
Value |
$3,168,069,407 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
11
|
2
|
Stock
price went up :
|
4
|
0
|
Stock
price went down : |
7
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
-2.0
|
Percentage
Gain/Loss : |
-12.8%
|
-42.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Arena Pharmaceuticals Inc |
ARNA |
Director, 10% Owner |
2003-10-17 |
0 |
2003-10-17 |
4,520,212 |
Premium* |
|
Repligen Corp |
RGEN |
10% Owner |
2009-05-15 |
3,216,850 |
|
0 |
Premium* |
|
Dynavax Technologies Corp |
DVAX |
Indirect Beneficial Ow... |
2009-06-19 |
6,193,051 |
2009-06-19 |
18,579,153 |
Premium* |
|
Adolor Corp |
ADLR |
10% Owner |
2009-09-22 |
4,123,551 |
2009-09-22 |
12,370,653 |
Premium* |
|
Gyre Therapeutics |
GYRE |
10% Owner |
|
0 |
2012-11-08 |
1,052,258 |
Premium* |
|
Arqule Inc |
ARQL |
10% Owner |
2018-05-30 |
771,305 |
2010-04-05 |
12,624,219 |
Premium* |
|
Astex Pharmaceuticals Inc |
ASTX |
10% Owner |
2010-04-20 |
5,583,399 |
2010-04-20 |
16,750,197 |
Premium* |
|
Capstone Therapeutics Corp |
CAPS |
See Explanation of Res... |
2011-06-27 |
0 |
2017-07-14 |
890,487 |
Premium* |
|
Ligand Pharmaceuticals Inc |
LGND |
See Explanation of Res... |
|
0 |
2014-03-25 |
130,175 |
Premium* |
|
Icagen Inc |
ICGN |
10% Owner |
2011-09-07 |
0 |
2011-09-07 |
625,400 |
Premium* |
|
Palatin Technologies Inc |
PTN |
10% Owner |
|
0 |
2014-02-27 |
2,494,521 |
Premium* |
|
Neurocrine Biosciences Inc |
NBIX |
10% Owner |
2011-10-10 |
0 |
2011-10-12 |
3,527,700 |
Premium* |
|
Kent International Inc |
KNTH |
See Explanation of Res... |
2011-12-23 |
0 |
2011-12-23 |
0 |
Premium* |
|
Chemocentryx, Inc. |
CCXI |
10% Owner |
|
0 |
2012-11-06 |
3,750,277 |
Premium* |
|
Rigel Pharmaceuticals Inc |
RIGL |
10% Owner |
|
0 |
2013-06-07 |
7,761,738 |
Premium* |
|
Cascadian Therapeutics, Inc |
CASC |
10% Owner |
2013-06-05 |
0 |
2015-02-05 |
1,898,293 |
Premium* |
|
Tobira Therapeutics Inc |
TBRA |
See Explanation of Res... |
|
0 |
2014-03-21 |
1,121,221 |
Premium* |
|
Cti Biopharma Corporation |
CTIC |
See Explanation of Res... |
2023-06-26 |
0 |
2023-06-26 |
0 |
Premium* |
|
Infinity Pharmaceuticals Inc |
INFI |
10% Owner |
2021-02-11 |
534,847 |
2016-12-01 |
0 |
Premium* |
|
XOMA Corporation |
XOMA |
Director, 10% Owner |
2023-01-06 |
1,693,924 |
2023-01-06 |
361,774 |
Premium* |
|
Alpine Immune Sciences Inc |
ALPN |
10% Owner |
2017-06-20 |
201,811 |
2017-05-09 |
0 |
Premium* |
|
Glycomimetics Inc |
GLYC |
10% Owner |
2020-11-04 |
630,453 |
|
0 |
Premium* |
|
Xenon Pharmaceuticals Inc. |
XENE |
10% Owner |
2018-03-27 |
59,464 |
2017-06-06 |
0 |
Premium* |
|
Concert Pharmaceuticals, Inc. |
CNCE |
10% Owner |
2019-06-10 |
169,589 |
2017-10-19 |
0 |
Premium* |
|
Syndax Pharmaceuticals Inc |
SNDX |
10% Owner |
2018-06-18 |
85,038 |
2018-06-18 |
0 |
Premium* |
|
Immune Design Corp. |
IMDZ |
10% Owner |
2018-12-04 |
370,391 |
2018-12-04 |
0 |
Premium* |
|
Pieris Pharmaceuticals, Inc. |
PIRS |
10% Owner |
2023-05-11 |
20,333,557 |
2019-01-30 |
0 |
Premium* |
|
Calithera Biosciences, Inc. |
CALA |
10% Owner |
2020-05-21 |
480,432 |
|
0 |
Premium* |
|
Five Prime Therapeutics Inc |
FPRX |
10% Owner |
2021-03-04 |
6,262,085 |
|
0 |
Premium* |
|
Cytokinetics Inc |
CYTK |
See Explanation of Res... |
2020-12-09 |
463,244 |
2019-12-10 |
0 |
Premium* |
|
Merus Nv |
MRUS |
10% Owner |
2021-10-08 |
232,747 |
|
0 |
Premium* |
|
Ideaya Biosciences, Inc. |
IDYA |
See Explanation of Res... |
2021-02-02 |
233,150 |
2020-06-19 |
0 |
Premium* |
|
Kymera Therapeutics, Inc. |
KYMR |
See Remarks and Footno... |
2023-11-03 |
294,632 |
2020-08-21 |
0 |
Premium* |
|
Eledon Pharmaceuticals Ord Shs |
ELDN |
10% Owner |
2024-05-09 |
220,460 |
|
0 |
Premium* |
|
Olema Pharmaceuticals, Inc. |
OLMA |
Director, 10% Owner |
2023-09-12 |
524,151 |
2023-09-14 |
99,556 |
Premium* |
|
Cytomx Therapeutics, Inc. |
CTMX |
10% Owner |
2020-12-18 |
5,468,599 |
|
0 |
Premium* |
|
Rain Therapeutics Inc. |
RAIN |
See Remarks; Former 10... |
2024-01-25 |
0 |
2021-04-23 |
0 |
Premium* |
|
Repare Therapeutics Inc. |
RPTX |
10% Owner |
2023-11-16 |
548,938 |
|
0 |
Premium* |
|
Verastem, Inc. |
VSTM |
10% Owner |
2022-01-25 |
19,630,934 |
|
0 |
Premium* |
|
ESSA Pharma Inc |
EPIX |
10% Owner |
2022-07-11 |
8,561,841 |
|
0 |
Premium* |
|
Third Harmonic Bio, Inc. |
THRD |
10% Owner |
2022-12-20 |
241,309 |
2022-12-20 |
0 |
Premium* |
|
Structure Therapeutics Inc. |
GPCR |
10% Owner |
2023-05-10 |
5,173,941 |
|
0 |
Premium* |
|
Engene Holdings Inc. |
ENGN |
10% Owner |
2023-10-31 |
2,221,445 |
|
0 |
Premium* |
|
Allakos Inc. |
ALLK |
10% Owner |
2024-01-16 |
16,312,872 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
356 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 15
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CTIC |
Cti Biopharma Corporation |
10% Owner |
|
2017-06-09 |
4 |
A |
$0.00 |
$0 |
I/I |
357,333 |
2,083,651 |
0 |
- |
|
CTIC |
Cti Biopharma Corporation |
10% Owner |
|
2017-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
3,759,333 |
651,074 |
0 |
- |
|
KYMR |
Kymera Therapeutics, Inc. |
See Explanation of Responses |
|
2020-08-21 |
4 |
A |
$0.00 |
$0 |
D/D |
1,578,804 |
113,290 |
0 |
- |
|
KYMR |
Kymera Therapeutics, Inc. |
See Explanation of Responses |
|
2020-08-21 |
4 |
A |
$20.00 |
$19,573,860 |
D/D |
978,693 |
181,081 |
0 |
- |
|
OLMA |
Olema Pharmaceuticals, In... |
10% Owner |
|
2020-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,216,676 |
361,091 |
0 |
- |
|
ELDN |
Eledon Pharmaceuticals Or... |
See Explanation of Responses |
|
2020-12-22 |
4 |
A |
$0.00 |
$0 |
D/D |
1,289,628 |
113,152 |
0 |
- |
|
OLMA |
Olema Pharmaceuticals, In... |
10% Owner |
|
2021-03-31 |
4 |
A |
$0.00 |
$0 |
I/I |
99,556 |
99,556 |
0 |
- |
|
RAIN |
Rain Therapeutics Inc. |
See Explanation of Responses |
|
2021-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
3,578,262 |
286,691 |
0 |
- |
|
RAIN |
Rain Therapeutics Inc. |
See Explanation of Responses |
|
2021-04-23 |
4 |
A |
$15.93 |
$18,694,901 |
D/D |
1,105,896 |
86,479 |
0 |
- |
|
RAIN |
Rain Therapeutics Inc. |
See Explanation of Responses |
|
2021-04-23 |
4 |
A |
$0.00 |
$0 |
D/D |
217,033 |
17,390 |
0 |
- |
|
RAIN |
Rain Therapeutics Inc. |
See Explanation of Responses |
|
2021-04-26 |
4 |
A |
$14.90 |
$408,478 |
D/D |
27,413 |
88,226 |
0 |
- |
|
CTIC |
Cti Biopharma Corporation |
See Explanation of Responses |
|
2022-08-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,519,999 |
1,526,147 |
0 |
- |
|
CTIC |
Cti Biopharma Corporation |
See Explanation of Responses |
|
2022-08-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,863,332 |
702,505 |
0 |
- |
|
OLMA |
Olema Pharmaceuticals, In... |
Director |
|
2023-09-14 |
4 |
A |
$0.00 |
$0 |
I/I |
99,556 |
99,556 |
0 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-06-27 |
4 |
B |
$0.25 |
$14,175 |
I/I |
56,700 |
3,155,200 |
1.5 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-06-28 |
4 |
B |
$0.25 |
$7,600 |
I/I |
30,400 |
3,173,650 |
1.5 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-06-29 |
4 |
B |
$0.25 |
$3,215 |
I/I |
12,950 |
3,180,750 |
1.42 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-06-30 |
4 |
B |
$0.25 |
$1,172 |
I/I |
4,700 |
3,183,600 |
1.42 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-11 |
4 |
B |
$0.25 |
$2,250 |
I/I |
9,000 |
3,192,600 |
1.42 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-14 |
4 |
B |
$0.25 |
$4,925 |
I/I |
19,700 |
3,212,300 |
1.42 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-18 |
4 |
B |
$0.25 |
$84,420 |
I/I |
338,900 |
3,522,300 |
1.5 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-20 |
4 |
B |
$0.25 |
$63,099 |
I/I |
252,600 |
3,716,400 |
1.5 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-26 |
4 |
B |
$0.25 |
$4,600 |
I/I |
18,400 |
3,730,300 |
1.42 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-28 |
4 |
B |
$0.25 |
$5,763 |
I/I |
23,050 |
3,747,400 |
1.5 |
- |
|
CAPS |
Capstone Therapeutics Cor... |
See Explanation of Responses |
|
2011-07-29 |
4 |
B |
$0.25 |
$232,800 |
I/I |
931,200 |
4,345,900 |
1.5 |
- |
|
356 Records found
|
|
Page 1 of 15 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|